Comprehensive Treatment of Pancreatic Neuroendocrine Neoplasms_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIUHao ¹ ,  WUCheng-yi ² , LÜZhong-zhu ¹

1. Department of General Surgery, The People's Hospital of Bishan Distrct, Chongqing 402760, China;
2. Department of endocrinology and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

Corresponding author：

WUCheng-yi, Email: 498746093@qq.com

Keywords：

Irreversible electroporation; Tumor; Ablation

DOI：

10.7507/1007-9424.20160097

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summary the treatment of pancreatic neuroendocrine neoplasms (pNENs). Methods Articles relevant to pNENs at home and abroad were collected and reviewed. Results Because of rare incidence and non-specific clinical syndromes of pNENs, clinician had no enough cognition about it. For pNENs, surgery was still the preferred option, combining other treatments included chemotherapy, somatostatin analogue, α-interferon, molecular targeted therapy, and peptide receptor radionuclide therapy (PRRT). Conclusion Surgery is still considered as the preferred option for controlling the associated biochemical syndromes and curtailing the malignant progression of pNENs.

Citation： LIUHao, WUCheng-yi, LÜZhong-zhu. Comprehensive Treatment of Pancreatic Neuroendocrine Neoplasms. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(3): 369-373. doi: 10.7507/1007-9424.20160097 Copy

1.	盛伟琪. 胃肠胰神经内分泌肿瘤病理诊断的规范和进展. 中国癌症杂志, 2013, 23(6): 401-406.
2.	中国胃肠胰神经内分泌肿瘤病理专家组. 中国胃肠胰神经内分泌肿瘤病理学诊断共识(2013版). 中华病理学杂志, 2013, 42(10): 691-694.
3.	徐建明. 重视对胃肠胰神经内分泌肿瘤的认识. 中华肿瘤杂志, 2012, 34(2): 158-160.
4.	Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer, 2003, 97(4): 934-959.
5.	岑超平, 陈晓, 李冲, 等. 胰腺神经内分泌肿瘤诊治进展. 肿瘤基础与临床, 2015, 28(2): 178-180.
6.	CSCO神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识. 临床肿瘤学杂志, 2013, 18(9): 815-832.
7.	张太平, 熊光冰, 赵玉沛. 胰腺神经内分泌肿瘤诊治进展. 中华外科杂志, 2014, 52(9): 706-708.
8.	Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 2008, 9(1): 61-72.
9.	Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
10.	Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin, 2011, 61(2): 113-132.
11.	Grobmyer SR, Vogel SB, Mcguigan JE, et al. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: long-term results. J Am Coll Surg, 2009, 208(5): 718-722.
12.	Boudrcause JP. Surgery for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011, 40(1): 163-171.
13.	陈鑫, 吴诚义. 罕见胰腺内分泌肿瘤的诊治. 中国普外基础与临床杂志, 2012, 19(10): 1039-1043.
14.	颜兆寰, 温巧生, 王滔明, 等. 胃泌素瘤的诊断及预后. 实用医学杂志, 2010, 26(22): 4222-4223.
15.	刘勇峰, 梅乐园, 贺爱军, 等. 腹腔镜胰体尾脾切除术治疗胰高血糖素瘤1例报告. 腹腔镜外科杂志, 2011, 16(5): 398-399.
16.	张正筠, 周光文, 申川, 等. 肝移植治疗胰腺生长抑素瘤肝转移一例. 中华外科杂志, 2007, 45(15): 1075-1076.
17.	Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res, 2004, 120(1): 139-161.
18.	Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol, 2004, 22(23): 4762-4771.
19.	Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab, 2009, 94(4): 1074-1080.
20.	中华医学会外科学分会胰腺外科学组. 胰腺神经内分泌肿瘤治疗指南（2014）. 中国实用外科杂志, 2014, 34(12): 1117-1119.
21.	Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol, 2010, 17(12): 3129-3136.
22.	Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol, 2012, 30(24): 2963-2968.
23.	Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
24.	Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 501-513.
25.	Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117(2): 268-275.
26.	Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, 117(20): 4617-4622.
27.	Pavel ME, Wiedenman B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
28.	中华医学会肿瘤学分会胰腺癌学组. 胰腺神经内分泌肿瘤诊治专家共识. 中华肿瘤杂志, 2014, 36(9): 717-720.
29.	Oberg K, Ferone D, Kaltsas G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology, 2009, 90(2): 209-213.
30.	梁后杰, 杨晨. 胃肠胰腺神经内分泌肿瘤治疗共识(NCCN、ENETs、NANETs)解读. 临床肿瘤学杂志, 2011, 16(11): 1039-1043.
31.	Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 2008, 26(20): 3403-3410.
32.	Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol, 2010, 28(6): 1075-1083.
33.	Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 514-523.
34.	Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide rece-ptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med, 2010, 40(2): 78-88.
35.	刘毫, 吴诚义, 朱之坤, 等. 胰高血糖素瘤的诊治现状. 中华内分泌外科杂志, 2014, 8(3): 243-245.
36.	Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol, 2008, 26(13): 2124-2130.

1. 盛伟琪. 胃肠胰神经内分泌肿瘤病理诊断的规范和进展. 中国癌症杂志, 2013, 23(6): 401-406.
2. 中国胃肠胰神经内分泌肿瘤病理专家组. 中国胃肠胰神经内分泌肿瘤病理学诊断共识(2013版). 中华病理学杂志, 2013, 42(10): 691-694.
3. 徐建明. 重视对胃肠胰神经内分泌肿瘤的认识. 中华肿瘤杂志, 2012, 34(2): 158-160.
4. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer, 2003, 97(4): 934-959.
5. 岑超平, 陈晓, 李冲, 等. 胰腺神经内分泌肿瘤诊治进展. 肿瘤基础与临床, 2015, 28(2): 178-180.
6. CSCO神经内分泌肿瘤专家委员会. 中国胃肠胰神经内分泌肿瘤专家共识. 临床肿瘤学杂志, 2013, 18(9): 815-832.
7. 张太平, 熊光冰, 赵玉沛. 胰腺神经内分泌肿瘤诊治进展. 中华外科杂志, 2014, 52(9): 706-708.
8. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol, 2008, 9(1): 61-72.
9. Halvorson SA, Gilbert E, Hopkins RS, et al. Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. J Gen Intern Med, 2013, 28(11): 1525-1529.
10. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin, 2011, 61(2): 113-132.
11. Grobmyer SR, Vogel SB, Mcguigan JE, et al. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: long-term results. J Am Coll Surg, 2009, 208(5): 718-722.
12. Boudrcause JP. Surgery for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am, 2011, 40(1): 163-171.
13. 陈鑫, 吴诚义. 罕见胰腺内分泌肿瘤的诊治. 中国普外基础与临床杂志, 2012, 19(10): 1039-1043.
14. 颜兆寰, 温巧生, 王滔明, 等. 胃泌素瘤的诊断及预后. 实用医学杂志, 2010, 26(22): 4222-4223.
15. 刘勇峰, 梅乐园, 贺爱军, 等. 腹腔镜胰体尾脾切除术治疗胰高血糖素瘤1例报告. 腹腔镜外科杂志, 2011, 16(5): 398-399.
16. 张正筠, 周光文, 申川, 等. 肝移植治疗胰腺生长抑素瘤肝转移一例. 中华外科杂志, 2007, 45(15): 1075-1076.
17. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res, 2004, 120(1): 139-161.
18. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol, 2004, 22(23): 4762-4771.
19. Guettier JM, Kam A, Chang R, et al. Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab, 2009, 94(4): 1074-1080.
20. 中华医学会外科学分会胰腺外科学组. 胰腺神经内分泌肿瘤治疗指南（2014）. 中国实用外科杂志, 2014, 34(12): 1117-1119.
21. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol, 2010, 17(12): 3129-3136.
22. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol, 2012, 30(24): 2963-2968.
23. Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev, 2011, 37(2): 127-132.
24. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 501-513.
25. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117(2): 268-275.
26. Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, 117(20): 4617-4622.
27. Pavel ME, Wiedenman B. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors. Horm Metab Res, 2011, 43(12): 844-853.
28. 中华医学会肿瘤学分会胰腺癌学组. 胰腺神经内分泌肿瘤诊治专家共识. 中华肿瘤杂志, 2014, 36(9): 717-720.
29. Oberg K, Ferone D, Kaltsas G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology, 2009, 90(2): 209-213.
30. 梁后杰, 杨晨. 胃肠胰腺神经内分泌肿瘤治疗共识(NCCN、ENETs、NANETs)解读. 临床肿瘤学杂志, 2011, 16(11): 1039-1043.
31. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 2008, 26(20): 3403-3410.
32. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol, 2010, 28(6): 1075-1083.
33. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011, 364(6): 514-523.
34. Kwekkeboom DJ, de Herder WW, van Eijck CH, et al. Peptide rece-ptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med, 2010, 40(2): 78-88.
35. 刘毫, 吴诚义, 朱之坤, 等. 胰高血糖素瘤的诊治现状. 中华内分泌外科杂志, 2014, 8(3): 243-245.
36. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol, 2008, 26(13): 2124-2130.

Previous Article
A New and Minimally Invasive Ablation Technology for Tumors——Irreversible Electro-poration
Next Article
Application of Tranexamic Acid in Patients with Trauma-Related Hemorrhage

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Comprehensive Treatment of Pancreatic Neuroendocrine Neoplasms

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content